Cargando…
Increasing Access to Hepatitis C Virus Medications: A Program Model Using Patient Navigators and Specialty Pharmacy to Obtain Prior Authorization Approval
BACKGROUND: Obtaining prior authorization (PA) approval for the new direct-acting antiviral (DAA) hepatitis C medications is time consuming and requires specific expertise. Our primary care-based program treats hepatitis C virus (HCV)-infected patients at an urban academic medical center and employs...
Autores principales: | Vu, Trang M., Toribio, Wilma, Riazi, Farah, Ciprian, Genesis, Gibbs, Nathalia, Giardina, Martha, Camacho, Jocelyn A., Parrella, Korin, Cambe, Joy, Amory, Catherine, Chasan, Rachel, Sigel, Keith M., Weiss, Jeffrey J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6862767/ https://www.ncbi.nlm.nih.gov/pubmed/29578854 http://dx.doi.org/10.18553/jmcp.2018.24.4.329 |
Ejemplares similares
-
Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City
por: Ziff, Jacob, et al.
Publicado: (2021) -
Community Case Study of Naloxone Distribution by Hospital-Based Harm Reduction Program for People Who Use Drugs in New York City
por: Riazi, Farah, et al.
Publicado: (2021) -
The Emergence of Specialty Pharmacy
por: Vanscoy, Gordon J.
Publicado: (2020) -
The Reemergence of Specialty Pharmacy
por: Vanscoy, Gannon, et al.
Publicado: (2020) -
Management of specialty drugs, specialty pharmacies and biosimilars in the United States
por: Brook, Richard A., et al.
Publicado: (2019)